The role of lapatinib in HER2-positive breast cancer
Journal Title: OncoReview - Year 2013, Vol 3, Issue 2
Abstract
HER2 positive breast cancer presents 25–35% of newly diagnosed cases and is associated with more aggressiveness and poorer prognosis. The anti-HER2 monoclonal antibody trastuzumab improved the outcome of women with HER positive breast cancer. Despite the primary effectiveness resistance to trastuzumab occurs. The second drug which interacts with HER2 receptor is lapatinib. There is no cross resistance between both drugs. Lapatinib is dual, reversible tyrosin kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Based on the results of the clinical trials the efficacy and safety of lapatinib was confirmed.
Authors and Affiliations
Małgorzata Kuc-Rajca, Tadeusz Pieńkowski, Anna Walaszkowska-Czyż
Keywords
Related Articles
- EP ID EP53216
- DOI -
- Views 196
- Downloads 0
Liposomal doxorubicin in first line metastatic HER-2-positive breast cancer for prevention the cardiotoxicity
We describe a 62 year old female with metastatic HER-2-positive breast cancer, and with independent cardiovascular comorbidities. She was earlier treated with J131 therapy due to thyroid toxicity. She developed grade 2 m...
Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?
Myocardial dysfunction related to trastuzumab therapy – is effective treatment always possible?
Left ventricle systolic dysfunction manifesting during trastuzumab treatment is defined as cardiotoxicity type II. It is characterized by full reversibility after discontinuation of trastuzumab and cardiological pharmaco...
Ifosfamide-induced encephalopathy in a patient with metastatic fibrosarcoma
Ifosfamide is a cytostatic drug commonly used in chemotherapy. One of the common adverse effects resulting from the treatment with ifosfamide is encephalopathy. This paper describes a case study of a 64-year-old patient...
Sequential oncological therapy and delays in oncological diagnostics and treatment
One of the causes behind the low recovery rate among oncological patients is late diagnosis and delayed treatment. To a large extent it stems from the limited access to standard diagnostic methods, and from the extended...